BioWorld

June 18, 2003

MedImmune's Intranasal Vaccine FluMist Receives FDA Approval

MedImmune Inc. received long-awaited news late Tuesday afternoon as the FDA approved FluMist, a nasally delivered product that has ridden a rocky road throughout the regulatory review process. (BioWorld Today) Read More

Cell Therapeutics, Novuspharma Merging In $236M Stock Exchange

Alcohol Abuse In Pregnancy Can Bring On Fetal Alcohol Syndrome, Mental Retardation In The Young

Biomira, Merck KGaA Report Failed Theratope Phase III Trial

BioMarin Aiming To Raise $125M In Convertible Notes

Questcor Raises $5M To Fund $18.2M Purchase Of Nascobal

Boston Life Sciences Plans Another Altropane Phase III

Amylin Sends Symlin Amendment To FDA, Seeks $150M In Notes

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Feb. 10, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 10, 2026